Top

Dermatology and Therapy

Published in:

Open Access 01-02-2022 | Vulgar Psoriasis | Original Research

The Impact of Stress-Coping Strategies and the Severity of Psoriasis on Self-Esteem, Illness Acceptance and Life Satisfaction

Authors: Beata Kowalewska, Elżbieta Krajewska-Kułak, Marek Sobolewski

Published in: Dermatology and Therapy | Issue 2/2022

Abstract

Introduction

The visibility of skin lesions is a significant burden for patients with psoriasis, who experience social hostility as well as many emotional and psychological problems. The recurrent nature of cutaneous manifestations and their location are also a source of emotional distress, which in turn is one of the main factors that intensifies skin lesions in these patients. The aim of the study was to assess the impact of the severity of psoriasis and stress-coping strategies on general psychometric measures in the affected patients.

Methods

The study used a short demographic questionnaire, Psoriasis Area and Severity Index (PASI), and four standardised general psychometric tools: Rosenberg Self-Esteem Scale (SES), Satisfaction With Life Scale (SWLS), Coping Inventory for Stressful Situations (CISS) and Acceptance of Illness Scale (AIS). A total of 111 patients participated in the study.

Results

The mean PASI score was 14.0 (12.1–15.9). The mean SWLS score was below average, i.e., 18.5 (17.3–19.7), and the SES score—26.8 points (26.1–27.5)—indicated self-esteem slightly above average among patients with psoriasis. The mean stress-coping level measured with CISS was 53.6 (51.9–55.2) for the task-oriented strategy (TOS), 46.2 (43.8–48.6) for the emotion-oriented strategy (EOS) and 50.1 (48.5–51.8) for the avoidance-oriented strategy (AOS). Higher PASI was associated with lower illness acceptance among men (r = 0.48) and lower self-esteem among women (r = 0.44). The level of life satisfaction was lower in respondents with higher PASI scores (mainly in the group of women, r = 0.44).

Conclusions

Higher severity of psoriasis (PASI) and greater frequency of emotion-oriented stress-coping mechanisms (CISS) are factors that negatively affect the overall psychophysical condition of respondents.

Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronić skin disease. Dermatol Ther. 2008;21:54–9. https://doi.org/10.1111/j.1529-8019.2008.00170.x.CrossRefPubMed

Inanir I, Aydemir O, Gündüz K, Danaci AE, Türel A. Developing a quality of life instrument in patients with psoriasis: the Psoriasis Quality of Life Questionnaire (PQLQ). Int J Dermatol. 2006;45:234–8. https://doi.org/10.1111/j.1365-4632.2005.02448.x.CrossRefPubMed

Kong Y, Zhang S, Wu R, Su X, Peng D, Zhao M, Su Y. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019;18(1):171. https://doi.org/10.1186/s12944-019-1115-3.CrossRefPubMedPubMedCentral

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475.CrossRefPubMedCentral

Frischknecht L, Vecellio M, Selmi C. The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis. Ther Adv Musculoskelet Dis. 2019;11:17–59. https://doi.org/10.1177/1759720X19886505.CrossRef

Drvar DL, Vlahinić T, Maleš Ž, Turčić P, Čeović R. A modern approach to the treatment of plaque psoriasis. Acta Pharm. 2019;69(4):511–23. https://doi.org/10.2478/acph-2019-0047.CrossRefPubMed

Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–23. https://doi.org/10.1136/ard.2004.033217.CrossRefPubMedPubMedCentral

Oji V, Luger TA. The skin in psoriasis: assessment and challenges. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S14–9.PubMed

Petraškienė R, Valiukevičienė S, Macijauskienė J. Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis. Medicina. 2016;52(4):238–43. https://doi.org/10.1016/j.medici.2016.07.001.CrossRefPubMed

10.

Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94. https://doi.org/10.1016/S0140-6736(14)61909-7.CrossRefPubMed

11.

Zięciak T, Rzepa T, Król J, Żaba R. Stigmatization feelings and depression symptoms in psoriasis patients. Psychiatr Pol. 2017;51:1153–63. https://doi.org/10.12740/PP/68848.CrossRefPubMed

12.

Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol. 2007;25:547–54. https://doi.org/10.1016/j.clindermatol.2007.08.008.CrossRefPubMed

13.

Zill JM, Dirmaier J, Augustin M, et al. Psychosocial distress of patients with psoriasis: protocol for an assessment of care needs and the development of a supportive intervention. JMIR Res Protoc. 2018;7: e22. https://doi.org/10.2196/resprot.8490.CrossRefPubMedPubMedCentral

14.

Kostyła M, Tabała K, Kocur J. Illness acceptance degree versus intensity of psychopathological symptoms in patients with psoriasis. Adv Dermatol Allergol. 2013;30:134–9. https://doi.org/10.5114/pdia.2013.35613.CrossRef

15.

Hrehorów E, Reich A, Szepietowski J. Jakość życia chorych na łuszczycę: zależność od świądu, stresu i objawów depresyjnych. Dermatol Klin. 2007;9:19–23.

16.

Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, Gutiérrez-Rojas L, González-Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: a case–control study. J Psychosom Res. 2019. https://doi.org/10.1016/j.jpsychores.2019.109780.CrossRefPubMed

17.

Gupta MA, Gupta AK. Psychiatric and psychological comorbidity in patients with dermatologic disorders: epidemiology and management. An J Clin Dermatol. 2003;4(12):833–42. https://doi.org/10.2165/00128071-200304120-00003.CrossRef

18.

Miękoś-Zydek B, Ryglewska A, Lassota-Falczewska M, Czyż P, Kaszuta A. Quality of life in psoriatic patients. Adv Dermatol Allergol. 2006;23(6):273–7.

19.

Rapp DA, Brenes GA, Felman SR, et al. Anger and acne: implications for quality of life, patient satisfaction and clinical care. Br J Dermatol. 2004;151(1):183–9. https://doi.org/10.1111/j.1365-2133.2004.06078.x.CrossRefPubMed

20.

Zacharie R, Zacharie C, Ibsen H, Morternsen JT, Wulf HC. Dermatology life quality idem: data Danish inpatients and outpatients. Acta Derm Venerol. 2003. https://doi.org/10.1080/000155500750012153.CrossRef

21.

Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology. 2010;220:38–43. https://doi.org/10.1159/000265557.CrossRefPubMed

22.

Fortes C, Mastroeni S, Leffondré K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580–4. https://doi.org/10.1001/archderm.141.12.1580.CrossRefPubMed

23.

Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CE. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol. 2008;158:138–40. https://doi.org/10.1111/j.1365-2133.2007.08299.x.CrossRefPubMed

24.

TürelErmertcan A, Temeltaş G, Deveci A, et al. Sexual dysfunction in patients with psoriasis. J Dermatol. 2006;33:772–8. https://doi.org/10.1111/j.1346-8138.2006.00179.x.CrossRef

25.

Dauendorffer JN, Ly S, Beylot-Barry M. Psoriasis and male sexuality. Ann Dermatol Venereol. 2019;146(4):273–8. https://doi.org/10.1016/j.annder.2019.01.021.CrossRefPubMed

26.

Diener E, Emmons RA, Larsen RJ, Griffin S. The satisfaction with life scale. J Pers Assess. 1985;49(1):71–5. https://doi.org/10.1207/s15327752jpa4901_13.CrossRefPubMed

27.

Juczyński Z. NPPPZ—Narzędzia Pomiaru w Promocji i Psychologii Zdrowia. Pracownia Testów Psychologicznych Polskiego Towarzystwa Psychologicznego, Warszawa 2012.

28.

Dzwonkowska I, Lachowicz-Tabaczek K, Łaguna M. Samoocena i jej pomiar. SES. Skala Samooceny Rosenberga. Pracownia Testów Psychologicznych, Warszawa 2008.

29.

Endler NS, Parker JDA. Coping Inventory for Stressful Situations (CISS). Manual, Multi-Health Systems, Toronto; 1990.

30.

Jaworowska A. CISS. In: Słownik psychologii, red. J. Siuta, KWN, Kraków; 2009. p. 348.

31.

Tomczak K. Style radzenia sobie w sytuacji stresowej, przekonanie o własnej skuteczności, nadzieja na sukces u studentów rozpoczynających i kończących studia. Psychoterapia. 2009;2(149):67–79.

32.

Strelau J, Jaworowska A, Wrześniewski K, Szczepaniak P. Kwestionariusz Radzenia Sobie w Sytuacjach Stresowych (CISS). Pracownia Testów Psychologicznych Polskiego Towarzystwa Psychologicznego, Warszawa; 2013.

33.

Felton BJ, Revenson TA. Coping with chronic illness: a study of illness controllability and the influence of coping strategies on psychological adjustment. J Consult Clin Psychol. 1984;52:343–53. https://doi.org/10.1037//0022-006x.52.3.343.CrossRefPubMed

34.

Bożek A, Reich A. How to assess the severity of psoriasis accurately? Forum Derm. 2016;2(1):6–11.

35.

Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44. https://doi.org/10.1159/000250839.CrossRefPubMed

36.

Stanisz A. Przystępny kurs statystyki z zastosowaniem STATISTICA PL na przykładach z medycyny. Tom 1. Wyd. StatSoft Polska, Kraków; 2007.

37.

Stanisz A. Przystępny kurs statystyki z zastosowaniem STATISTICA PL na przykładach z medycyny. Tom 2. Wyd. StatSoft Polska, Kraków; 2007.

38.

Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatol Treat. 2017;28(6):488–91. https://doi.org/10.1080/09546634.2016.1278198.].CrossRef

39.

Çakmur H, Derviş E. The relationship between quality of life and the severity of psoriasis in Turkey. Eur J Dermatol. 2015;25(2):169–76. https://doi.org/10.1684/ejd.2014.2511.CrossRefPubMed

40.

Reich A, Welz-Kubiak K, Rams L. Apprehension of the disease by patients suffering from psoriasis. Postepy Dermatol Alergol. 2014;31(5):289–93. https://doi.org/10.5114/pdia.2014.44010.CrossRefPubMedPubMedCentral

41.

Eskin M, Savk E, Uslu M, Küçükaydoğan N. Social problem-solving, perceived stress, negative life events, depression and life satisfaction in psoriasis. J Eur Acad Dermatol Venereol. 2014;28(11):1553–9. https://doi.org/10.1111/jdv.12355.CrossRefPubMed

42.

Kowalewska B, Cybulski M, Jankowiak B, Krajewska-Kułak E. Acceptance of illness, satisfaction with life, sense of stigmatization, and quality of life among people with psoriasis: a cross-sectional study. Dermatol Ther. 2020;10:413–30. https://doi.org/10.1007/s13555-020-00368-w.CrossRef

43.

Solovan C, Marcu M, Chiticariu E. Life satisfaction and beliefs about self and the world in patients with psoriasis: a brief assessment. Eur J Dermatol. 2014;24(2):242–7. https://doi.org/10.1684/ejd.2014.2295.CrossRefPubMed

44.

Basińska MA, Drozdowska M. Emotional intelligence as an indicator of satisfaction with life of patients with psoriasis. Postepy Dermatol Alergol. 2013;30(6):365–72. https://doi.org/10.5114/pdia.2013.39435.CrossRefPubMedPubMedCentral

45.

Rzeszutek M, Podkowa K, Pięta M, Pankowski D, Cyran-Stemplewska S. Comparative study of life satisfaction among patients with psoriasis versus healthy comparison group: the explanatory role of body image and resource profiles. Qual Life Res. 2021;30(1):181–91. https://doi.org/10.1007/s11136-020-02621-3.CrossRefPubMed

46.

Soliman MM. Feeling of stigmatization and satisfaction with life among Arabic psoriatic patients. Saudi Pharm J. 2020;28(12):1868–73. https://doi.org/10.1016/j.jsps.2020.11.013.CrossRefPubMedPubMedCentral

47.

Kowalewska B, Jankowiak B, Niedżwiecka B, Krajewska-Kułak E, Niczyporuk W, Khvorik DF. Relationships between the acceptance of illness, quality of life and satisfaction with life in psoriasis. Postepy Dermatol Alergol. 2020;37(6):948–55. https://doi.org/10.5114/ada.2020.92906.CrossRefPubMedPubMedCentral

48.

Kouris A, Christodoulou C, Stefanaki C, Livaditis M, Tsatovidou R, Kouskoukis C, Petridis A, Kontochristopoulos G. Quality of life and psychosocial aspects in Greek patients with psoriasis: a cross-sectional study. An Bras Dermatol. 2015;90(6):841–5. https://doi.org/10.1590/abd1806-4841.20154147.CrossRefPubMedPubMedCentral

49.

Hassani F, Koraei A, Yaghoobi R, Zarea K. An evaluating of the relationship between body image, body satisfaction, depression, marital quality, and self-esteem in patients with psoriasis. Psychol Health Med. 2021;26(4):467–77. https://doi.org/10.1080/13548506.2020.1766093.CrossRefPubMed

50.

Alariny AF, Farid CI, Elweshahi HM, Abbood SS. Psychological and sexual consequences of psoriasis vulgaris on patients and their partners. J Sex Med. 2019;16(12):1900–11. https://doi.org/10.1016/j.jsxm.2019.08.017.CrossRefPubMed

51.

Brihan I, Ianoşi SL, Boda D, Hălmăjan A, Zdrîncă M, Fekete LG. Implications of self-esteem in the quality of life in patients with psoriasis. Exp Ther Med. 2020;20(6):202. https://doi.org/10.3892/etm.2020.9332.CrossRefPubMedPubMedCentral

52.

Bitan D, Krieger I, Comaneshter D, Cohen AD, Feingold D. The association between the socioeconomic status and anxiety-depression comorbidity in patients with psoriasis: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2019;33(8):1555–61. https://doi.org/10.1111/jdv.15651.CrossRef

53.

Nazik H, Nazik S, Gul FC. Body image, self-esteem, and quality of life in patients with psoriasis. Indian Dermatol Online J. 2017;8(5):343–6. https://doi.org/10.4103/idoj.IDOJ_503_15.CrossRefPubMedPubMedCentral

54.

Słomian A, Łakuta P, Bergler-Czop B, Brzezińska-Wcisło L. Self-esteem is related to anxiety in psoriasis patients: a case control study. J Psychosom Res. 2018;114:45–9. https://doi.org/10.1016/j.jpsychores.2018.09.005.CrossRefPubMed

55.

Noormohammadpour P, Fakour Y, Nazemei MJ, Ehsani A, Gholamali F, Morteza A, Mokhtari L, Khosrovanmehr N. Evaluation of some psychological factors in psoriatic patients. Iran J Psychiatry. 2015;10(1):37–42.PubMedPubMedCentral

Title: The Impact of Stress-Coping Strategies and the Severity of Psoriasis on Self-Esteem, Illness Acceptance and Life Satisfaction
Authors: Beata Kowalewska
Elżbieta Krajewska-Kułak
Marek Sobolewski
Publication date: 01-02-2022
Publisher: Springer Healthcare
Keyword: Vulgar Psoriasis
Published in: Dermatology and Therapy / Issue 2/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-021-00669-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2022

Lentigo Maligna on a Difficult Location of the Face Treated with 5% Imiquimod: A Case Report of 2-Year Follow-Up

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line

Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study

Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases

Methoxy-Monobenzoylmethane Protects Skin from UV-Induced Damages in a Randomized, Placebo Controlled, Double-Blinded Human In Vivo Study and Prevents Signs of Inflammation While Improving the Skin Barrier

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage